Medicago signs MOU with NITT Partners for commercial development of influenza vaccines in Japan
Medicago Inc. announced that it has signed a Memorandum of Understanding with Niigata TLO/NBRP/KUTLO-NITT ("NITT Partners") to discuss and negotiate an agreement to commercialize Medicago's pandemic and seasonal influenza VLP-based vaccines in Japan and other territories. For several years, NITT Partners has been the government approved technology transfer/licensing organization to license in state of the art technologies. Under the terms of the MOU, the parties will evaluate and select an optimal deal structure with the objective of formalizing a definitive agreement.
"We are delighted to be collaborating with NITT Partners to potentially enable funding to support the development of our VLP-based influenza vaccines in Japan," Andy Sheldon, President and CEO of Medicago. "This further validates our unique plant-based vaccine technology offering of a rapid, affordable and effective solution for the supply of vaccines within country borders."
"The successful completion of our Phase I clinical trial for our H5N1 vaccine candidate has opened additional global doors and has also advanced the ongoing discussions with our potential partners," said Frederic Ors, VP Business Development of Medicago. "As we advance the clinical development of our vaccine candidates, we will continue to discuss opportunities with other pharmaceutical companies and governments to roll-out our compelling influenza vaccine technology around the globe."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
